Total | Grade | |||
---|---|---|---|---|
N(%) | 1 | 2 | 3 – 4 | |
Sirolimus (n = 23) | ||||
At least 1 toxicity reported | 14 (60) | |||
Intestinal toxicity | 8 (34) | 7 | 1 | |
Skin toxicity, infections | 1 (4) | 1 | 1 | |
Hematologic toxicity | 6 (26) | 1 | 1 | 4 |
Urinary toxicity | 1 (4) | 1 | ||
Neurological toxicity | 3 (13) | 2 | 1 | |
Other (fatigue, pain) | 6 (26) | 4 | 2 | |
Dose modification | 2 (9) | |||
Discontinuation for toxicity | 1 (4) | |||
Sunitinib (n = 5) | ||||
At least 1 toxicity reported | 4 (80) | |||
Hematologic toxicity | 2 (40) | 2 | ||
Pulmonary toxicity | 1 (20) | 1 | ||
Other (fatigue) | 2 (40) | 2 | 1 | |
Dose modification | 1 (20) | |||
Sorafenib (n = 4) | ||||
At least 1 toxicity reported | 3 (75) | |||
Skin toxicity, infections | 2 (50) | 1 | 1 | |
other (fatigue, psychological) | 4 (100) | 1 | 2 | |
Dose modification | 2 (50) | |||
Pazopanib (n = 1) | ||||
At least 1 toxicity reported | 1 | |||
Intestinal toxicity | 1 | 1 | ||
Other (fatigue) | 1 | 1 | ||
Dose modification | 0 | |||
Total | ≥1 AE: 22 | 17 | 11 | 11 |